Warfarin Dose Calculator
Estimate warfarin maintenance doses based on INR results and dosing algorithms. Enter values for instant results with step-by-step formulas.
Formula
Adjusted Weekly Dose = Current Weekly Dose x (1 + Adjustment %)
The dose adjustment percentage is determined by how far the current INR deviates from the target range. Subtherapeutic INR requires dose increases of 5-20%, while supratherapeutic INR requires decreases of 5-25% or dose holds depending on severity. Weekly doses are used because they allow flexible scheduling of different daily doses to achieve precise averages.
Worked Examples
Example 1: Subtherapeutic INR Adjustment
Problem: A patient on warfarin 5 mg daily (35 mg/week) for atrial fibrillation has an INR of 1.6. Target range is 2.0-3.0. Calculate the dose adjustment.
Solution: Current weekly dose: 35 mg\nINR 1.6 is subtherapeutic (below 2.0)\nRecommended increase: 10-15%\nNew weekly dose: 35 x 1.10 = 38.5 mg/week\nNew average daily dose: 38.5 / 7 = 5.5 mg/day\nSchedule: 5 mg x 4 days + 6 mg x 3 days = 38 mg/week
Result: Increase weekly dose from 35 mg to 38.5 mg | Recheck INR in 1-2 weeks
Example 2: Supratherapeutic INR Management
Problem: A patient on warfarin 7 mg daily (49 mg/week) has INR of 4.2. Target is 2.0-3.0. No active bleeding. Calculate adjustment.
Solution: Current weekly dose: 49 mg\nINR 4.2 is supratherapeutic (above 3.0 but below 5.0)\nHold 1-2 doses, then decrease by 10-20%\nNew weekly dose: 49 x 0.85 = 41.7 mg/week\nNew average daily dose: 41.7 / 7 = 5.95 mg/day\nSchedule: 6 mg daily (42 mg/week) after holding 1-2 doses
Result: Hold 1-2 doses, then resume at ~42 mg/week (6 mg/day) | Recheck in 3-5 days
Frequently Asked Questions
How does warfarin work as an anticoagulant?
Warfarin inhibits the enzyme vitamin K epoxide reductase, which is essential for recycling vitamin K into its active form. Active vitamin K is required for the hepatic synthesis of clotting factors II (prothrombin), VII, IX, and X, as well as the anticoagulant proteins C and S. By blocking vitamin K recycling, warfarin reduces the production of these clotting factors over several days. The full anticoagulant effect takes 5 to 7 days because existing clotting factors must be cleared from the circulation first, with factor VII having the shortest half-life of about 6 hours and factor II the longest at approximately 60 hours.
What factors can affect INR levels and warfarin dosing?
Numerous factors influence INR levels during warfarin therapy, making it one of the most challenging medications to manage. Dietary vitamin K intake from green leafy vegetables like spinach, kale, and broccoli can decrease INR levels if consumption increases. Hundreds of drug interactions exist, with antibiotics, antifungals, amiodarone, and NSAIDs being among the most clinically significant. Liver disease affects clotting factor synthesis and can potentiate warfarin effects. Genetic polymorphisms in CYP2C9 and VKORC1 genes can dramatically alter warfarin metabolism and sensitivity. Alcohol consumption, fever, diarrhea, and changes in thyroid function all independently affect INR stability.
How should warfarin be initiated in a new patient?
Warfarin initiation protocols generally start with a dose of 5 mg daily for most adults, though lower starting doses of 2 to 3 mg are recommended for elderly patients over 75, patients with liver disease, those with poor nutrition, patients taking interacting medications, and individuals with known CYP2C9 or VKORC1 genetic variants. The INR should be checked after the second or third dose and then every few days until a stable dose is established. During the initial period, bridging with a parenteral anticoagulant such as heparin or enoxaparin is necessary because warfarin initially creates a transient prothrombotic state by depleting protein C faster than the procoagulant factors.
How do genetic factors influence warfarin dosing requirements?
Pharmacogenomic testing for CYP2C9 and VKORC1 polymorphisms can help predict warfarin sensitivity and optimal dosing. CYP2C9 metabolizes S-warfarin, the more potent enantiomer, and patients with variant alleles like CYP2C9*2 and CYP2C9*3 metabolize warfarin more slowly, requiring 20 to 50 percent lower doses. VKORC1 polymorphisms affect the target enzyme sensitivity, with the -1639G>A variant being particularly common in Asian populations and associated with lower dose requirements. Combined CYP2C9 and VKORC1 genotyping can explain approximately 40 to 50 percent of warfarin dose variability. The FDA-approved warfarin label includes pharmacogenomic dosing tables, though routine genetic testing is not universally recommended.
What are the key drug interactions with warfarin?
Warfarin has one of the most extensive drug interaction profiles of any medication. Drugs that increase INR and bleeding risk include azole antifungals like fluconazole, macrolide antibiotics, fluoroquinolones, metronidazole, amiodarone, and acetaminophen at high doses exceeding 2 grams daily. Drugs that decrease INR include rifampin, carbamazepine, phenytoin, and barbiturates through CYP enzyme induction. NSAIDs and antiplatelet agents increase bleeding risk without necessarily changing the INR. Herbal supplements including St. John wort can reduce warfarin effect, while cranberry juice, garlic supplements, and ginkgo biloba may potentiate it. Patients should be counseled to report any medication changes to their anticoagulation provider.
When should warfarin be held before surgical procedures?
Warfarin should be discontinued 5 days before most surgical or invasive procedures to allow the INR to normalize below 1.5. The decision about bridging anticoagulation with heparin or LMWH during this period depends on the patient thrombotic risk. High-risk patients with mechanical mitral valves, recent VTE within 3 months, or CHA2DS2-VASc score of 7 or higher generally require bridging. Low-risk patients with atrial fibrillation and CHA2DS2-VASc below 5 can typically stop warfarin without bridging. The BRIDGE trial demonstrated that forgoing bridging in atrial fibrillation patients was noninferior for preventing thromboembolism and significantly reduced major bleeding. Warfarin can usually be restarted 12 to 24 hours postoperatively if hemostasis is adequate.